Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;49(1):15-21.
doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma

Byung Woog Kang  1 , Sang Kyun Sohn  1 , Joon Ho Moon  1 , Yee Soo Chae  1 , Jong Gwang Kim  1 , Soo Jung Lee  1 , Won Seog Kim  2 , Je-Jung Lee  3 , Se Ryeon Lee  4 , Keon Uk Park  5 , Ho Sup Lee  6 , Won Sik Lee  7 , Jong-Ho Won  8 , Moo-Rim Park  9 , Jae-Yong Kwak  10 , Min Kyoung Kim  11 , Hyo Jung Kim  12 , Sung Yong Oh  13 , Hye Jin Kang  14 , Cheolwon Suh  15
Affiliations

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma

Byung Woog Kang et al. Blood Res. 2014 Mar.

Abstract

Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea.

Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL.

Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS.

Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL.

Keywords: Chemotherapy; Epidemiology; Mantle cell lymphoma; Rituximab; Survival; Trend.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest relevant to this article were reported.

Figures

Fig. 1
Fig. 1
Kaplan-Meier analysis of overall survival and event-free survival.
Fig. 2
Fig. 2
Kaplan-Meier analysis of (A) overall survival and (B) event-free survival based on the International Prognostic Index.
Fig. 3
Fig. 3
Kaplan-Meier analysis of (A) overall survival and (B) event-free survival based on the Mantle Cell Lymphoma International Prognostic Index.
Fig. 4
Fig. 4
Kaplan-Meier analysis of (A) overall survival and (B) event-free survival based on rituximab-containing therapy as the first-line treatment.
See this image and copyright information in PMC

References

    1. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113:791–798. - PubMed
    1. Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013;54:1677–1683. - PubMed
    1. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood. 2009;114:1469–1476. - PubMed
    1. Chim CS, Chan AC, Choo CK, Kwong YL, Lie AK, Liang R. Mantle cell lymphoma in the Chinese: clinicopathological features and treatment outcome. Am J Hematol. 1998;59:295–301. - PubMed
    1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–518. - PubMed

LinkOut - more resources